Next Article in Journal
Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC
Next Article in Special Issue
Immunogenicity and Protection against Mycobacterium caprae Challenge in Goats Vaccinated with BCG and Revaccinated after One Year
Previous Article in Journal
Parental Vaccine Preferences for Their Children in China: A Discrete Choice Experiment
Open AccessReview

Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions

1
Department of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratory, Colorado State University, 1682 Campus Delivery, 200 West Lake Street, Fort Collins, CO 80523, USA
2
Department of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Denver, CO 80523, USA
3
Division of Pulmonary Sciences and Critical Care Medicine, Departments of Medicine and Academic Affairs, National Jewish Health, University of Colorado Anschutz Medical Campus, Denver, CO 80523, USA
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 688; https://doi.org/10.3390/vaccines8040688
Received: 27 September 2020 / Revised: 4 November 2020 / Accepted: 12 November 2020 / Published: 16 November 2020
(This article belongs to the Special Issue Development of Vaccines against Tuberculosis: One Health Approach)
The global tuberculosis (TB) epidemic caused by the bacterial pathogen Mycobacterium tuberculosis (M.tb) continues unabated. The Mycobacterium bovis bacillus Calmette–Guérin (BCG) vaccination is widely utilized worldwide to protect against infection with M.tb. BCG vaccine protection against TB has had widely varying results for reasons that are not well understood. BCG vaccine interference by non-tuberculosis (NTM) mycobacterial species has been implicated as the potential cause of reduced BCG vaccine efficacy against M.tb. Ongoing efforts to develop new vaccines for TB requires a thorough understanding of the effect of NTM exposure on BCG vaccine efficacy, which may ultimately be a critical determinant of success. We reviewed the conflicting reports on whether NTM interferes with the BCG vaccine, potential explanations to help resolve the controversy, and strategies for developing better animal models. Further studies are needed to longitudinally track the effects of NTM exposure on BCG vaccine-induced host-protective anti-TB immunity. View Full-Text
Keywords: Mycobacterium tuberculosis; non-tuberculosis mycobacteria; Bacille Calmette-Guérin Mycobacterium tuberculosis; non-tuberculosis mycobacteria; Bacille Calmette-Guérin
Show Figures

Figure 1

MDPI and ACS Style

Verma, D.; Chan, E.D.; Ordway, D.J. Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions. Vaccines 2020, 8, 688. https://doi.org/10.3390/vaccines8040688

AMA Style

Verma D, Chan ED, Ordway DJ. Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions. Vaccines. 2020; 8(4):688. https://doi.org/10.3390/vaccines8040688

Chicago/Turabian Style

Verma, Deepshikha; Chan, Edward D.; Ordway, Diane J. 2020. "Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions" Vaccines 8, no. 4: 688. https://doi.org/10.3390/vaccines8040688

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop